MAP2K7 and melanoma: To clarify the roles of AKT and BCL-2, we used AKT siRNA or navitoclax, respectively, the latter of which is a pro-apoptotic BH3-mimetic [64] used in clinical trials for melanoma and other cancers, along with BRAF/MEK inhibition [65].